Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia.

Literature DB >> 31416822

Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia.

Hyun Don Yun^1,2,3, Dawn K Schirm^1,2, Martin Felices^1,2, Jeffrey S Miller^1,2, Craig E Eckfeldt^1,2.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2019 PMID： 31416822 PMCID： PMC6712524 DOI： 10.1182/bloodadvances.2019000064

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

× No keyword cloud information.

12 in total

1. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells.

Authors: Gabrielle Romain; Vladimir Senyukov; Nicolas Rey-Villamizar; Amine Merouane; William Kelton; Ivan Liadi; Ankit Mahendra; Wissam Charab; George Georgiou; Badrinath Roysam; Dean A Lee; Navin Varadarajan
Journal: Blood Date: 2014-09-16 Impact factor: 22.113

2. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.

Authors: Sumithira Vasu; Shun He; Carolyn Cheney; Bhavani Gopalakrishnan; Rajeswaran Mani; Gerard Lozanski; Xiaokui Mo; Veronica Groh; Susan P Whitman; Renate Konopitzky; Christian Kössl; Donna Bucci; David M Lucas; Jianhua Yu; Michael A Caligiuri; William Blum; Paul J Adam; Eric Borges; Bjoern Rueter; Karl-Heinz Heider; Guido Marcucci; Natarajan Muthusamy
Journal: Blood Date: 2016-03-24 Impact factor: 22.113

3. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

Authors: Veronika Bachanova; Sarah Cooley; Todd E Defor; Michael R Verneris; Bin Zhang; David H McKenna; Julie Curtsinger; Angela Panoskaltsis-Mortari; Dixie Lewis; Keli Hippen; Philip McGlave; Daniel J Weisdorf; Bruce R Blazar; Jeffrey S Miller
Journal: Blood Date: 2014-04-09 Impact factor: 22.113

4. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

Authors: Jeffrey S Miller; Yvette Soignier; Angela Panoskaltsis-Mortari; Sarah A McNearney; Gong H Yun; Susan K Fautsch; David McKenna; Chap Le; Todd E Defor; Linda J Burns; Paul J Orchard; Bruce R Blazar; John E Wagner; Arne Slungaard; Daniel J Weisdorf; Ian J Okazaki; Philip B McGlave
Journal: Blood Date: 2005-01-04 Impact factor: 22.113

5. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Authors: David Parry; Timothy Guzi; Frances Shanahan; Nicole Davis; Deepa Prabhavalkar; Derek Wiswell; Wolfgang Seghezzi; Kamil Paruch; Michael P Dwyer; Ronald Doll; Amin Nomeir; William Windsor; Thierry Fischmann; Yaolin Wang; Martin Oft; Taiying Chen; Paul Kirschmeier; Emma M Lees
Journal: Mol Cancer Ther Date: 2010-07-27 Impact factor: 6.261

6. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Authors: Michelle K Gleason; Julie A Ross; Erica D Warlick; Troy C Lund; Michael R Verneris; Andres Wiernik; Stephen Spellman; Michael D Haagenson; Alexander J Lenvik; Mark R Litzow; Pearlie K Epling-Burnette; Bruce R Blazar; Louis M Weiner; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller
Journal: Blood Date: 2014-03-20 Impact factor: 22.113

7. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Authors: Michelle K Gleason; Michael R Verneris; Deborah A Todhunter; Bin Zhang; Valarie McCullar; Sophia X Zhou; Angela Panoskaltsis-Mortari; Louis M Weiner; Daniel A Vallera; Jeffrey S Miller
Journal: Mol Cancer Ther Date: 2012-10-17 Impact factor: 6.261

8. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Authors: Rizwan Romee; Maximillian Rosario; Melissa M Berrien-Elliott; Julia A Wagner; Brea A Jewell; Timothy Schappe; Jeffrey W Leong; Sara Abdel-Latif; Stephanie E Schneider; Sarah Willey; Carly C Neal; Liyang Yu; Stephen T Oh; Yi-Shan Lee; Arend Mulder; Frans Claas; Megan A Cooper; Todd A Fehniger
Journal: Sci Transl Med Date: 2016-09-21 Impact factor: 17.956

9. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.

Authors: Daniel A Vallera; Martin Felices; Ron McElmurry; Valarie McCullar; Xianzheng Zhou; Joerg Uwe Schmohl; Bin Zhang; Alexander J Lenvik; Angela Panoskaltsis-Mortari; Michael R Verneris; Jakub Tolar; Sarah Cooley; Daniel J Weisdorf; Bruce R Blazar; Jeffrey S Miller
Journal: Clin Cancer Res Date: 2016-02-04 Impact factor: 12.531

10. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.

Authors: E J Pomeroy; L A Lee; R D W Lee; D K Schirm; N A Temiz; J Ma; T A Gruber; E Diaz-Flores; B S Moriarity; J R Downing; K M Shannon; D A Largaespada; C E Eckfeldt
Journal: Oncogene Date: 2016-12-19 Impact factor: 9.867

5 in total

Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia.

1. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells.

2. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.

3. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

4. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

5. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

6. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

7. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

8. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

9. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.

10. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.

Review 1. Natural killer cells and acute myeloid leukemia: promises and challenges.

Review 2. Natural killer cell-based immunotherapy for acute myeloid leukemia.

3. Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E.

Review 4. Overcoming tumor resistance mechanisms in CAR-NK cell therapy.

Review 5. Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.